Brief: N4 Pharma Announces Positive Results From In Vivo Study Of Nuvec
May 12 (Reuters) - N4 Pharma PLC N4P.L: N4 PHARMA PLC: POSITIVE RESULTS FROM FIRST IN VIVO STUDY OF DUAL-LOADED NUVEC FOR IBD Source text: ID:nRSL1308Ia Further company coverage: N4P.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Thalia Therapeutics
See all newsThalia Therapeutics - Interim Results
Brief: Thalia Therapeutics Says New Patent Granted For Miristen In China
Thalia Therapeutics - New Patent Granted for miRisten in China
Thalia Therapeutics - RNA gene-silencing cardiovascular program advances
Thalia Therapeutics - Business Update and Notice of Results